At the time of infection, the therapeutic response to tyrosine kinase inhibitor was a complete hematological response which had 3.3% of patients, a complete cytogenetic response was found in 20%, while 73.4% of patients had a confirmed molecular response (MR) in the range of MR3 (BCR/ABL1 ratio ≤ 0.1% International Scale (IS)) which achieved 13.4% of patients to deep MR (MR4, BCR/ABL1 ratio ≤ 0.01% IS, and MR4.5, BCR/ABL1 ratio ≤ 0.0032% IS) which was confirmed in 60% of the patients. Here, ABL1 is linked to infection.